New antibody drug takes aim at Hard-to-Treat cancers

NCT ID NCT06380816

First seen May 08, 2026 · Last updated May 08, 2026

Summary

This early-phase trial tests a new drug called UCB4594 in people with advanced solid tumors (like lung, breast, or colon cancer) that haven't responded to standard treatments. The drug is an antibody designed to help the immune system attack cancer cells by targeting a protein called HLA-G. The study aims to find the safest dose, understand side effects, and see if the drug can shrink tumors.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOURS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Guy's Hopsital

    RECRUITING

    London, SE1 9RT, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Christie NHS Foundation Trust

    RECRUITING

    Manchester, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Newcastle upon Tyne Hospitals NHS Foundation Trust

    RECRUITING

    Newcastle upon Tyne, NE7 7DN, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • University Hospital Southampton NHS Foundation Trust

    NOT_YET_RECRUITING

    Southampton, United Kingdom

    Contact Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.